A Group Wide Biology and Banking Study for Phase II Study of R1507
Latest Information Update: 17 Sep 2021
Price :
$35 *
At a glance
- Drugs Teprotumumab (Primary)
- Indications Sarcoma
- Focus Biomarker; Pharmacodynamics
- 27 Nov 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 30 Sep 2013 New trial record
- 26 Sep 2013 According to the ClinicalTrials.gov record, the recruitment status of this study is unknown because the information has not been verified recently.